{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:14:46Z","timestamp":1791152086635,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":1111,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1111\/j.1524-4733.2010.00725.x","type":"journal-article","created":{"date-parts":[[2010,4,15]],"date-time":"2010-04-15T10:30:46Z","timestamp":1271327446000},"page":"657-666","source":"Crossref","is-referenced-by-count":176,"title":["A Review of Quantitative Risk\u2013Benefit Methodologies for Assessing Drug Safety and Efficacy\u2014Report of the ISPOR Risk\u2013Benefit Management Working Group"],"prefix":"10.1016","volume":"13","author":[{"given":"Jeff J.","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyang","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Lis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis W.","family":"Raisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1524-4733.2010.00725.x_bib10","author":"FDA"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib20","author":"FDA"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib30","author":"FDA"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib40","author":"FDA"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib50","author":"FDA"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib60","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/00002018-200528060-00001","article-title":"The precautionary principle and pharmaceutical risk management","volume":"28","author":"Callreus","year":"2005","journal-title":"Drug Saf"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib70","author":"FDA"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib80","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1001\/jama.295.17.2072","article-title":"How the US drug safety system should be changed","volume":"295","author":"Strom","year":"2006","journal-title":"JAMA"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib90","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJMsb053432","article-title":"Reform of drug regulation\u2014beyond an independent drug-safety board","volume":"354","author":"Ray","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib100","series-title":"Risk-Based Compliance Handbook (Chapter 7)","article-title":"Benefit risk assessment during research and development","author":"Schmitt","year":"2008"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib110","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJMp058029","article-title":"Safety in numbers\u2014monitoring risk in approved drugs","volume":"352","author":"Okie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib120","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1177\/009286159302700413","article-title":"Benefit risk assessment: what patients can know that scientists cannot","volume":"27","author":"Veatch","year":"1993","journal-title":"Drug Info J"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib130","series-title":"Pharmacovigilance","article-title":"Regulatory pharmacovigilance in the EU","author":"Bahri","year":"2007"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib140","author":"European Medicine Agency (EMEA) CHMP"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib150","series-title":"Pharmacoepidemiology and Therapeutic Risk Management (Chapter 29)","article-title":"The story of cisapride and its withdraw from market: a case study","author":"Guo","year":"2008"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib160","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/pds.771","article-title":"Practical pharmacovilance analysis and strategies","volume":"12","author":"Gould","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib170","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1377\/hlthaff.26.3.684","article-title":"Assessing a structured, quantitative health outcomes approach to drug risk\u2013benefit analysis","volume":"26","author":"Garrison","year":"2007","journal-title":"Health Aff"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib180","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jclinepi.2003.12.012","article-title":"Advances in risk\u2013benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis","volume":"57","author":"Lynd","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib190","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jclinepi.2004.03.015","article-title":"A Bayesian approach to evaluating net clinical benefit allowed for parameter uncertainty","volume":"58","author":"Sutton","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib200","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJM200006013422206","article-title":"Coverage by the news media of the benefits and risks of medications","volume":"342","author":"Moynihan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib210","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2165\/00002018-200326120-00002","article-title":"Benefit\u2013risk analysis: a brief review and proposed quantitative approaches","volume":"26","author":"Holden","year":"2003","journal-title":"Drug Saf"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib220","first-page":"12","article-title":"Risk benefit assessments","volume":"12","author":"Arlett","year":"2001","journal-title":"Pharm Physician"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib230","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00002018-199615010-00001","article-title":"Concepts in risk\u2013benefit assessment. A simple merit analysis of a medicine?","volume":"15","author":"Edwards","year":"1996","journal-title":"Drug Saf"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib240","author":"FDA"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib250","author":"FDA"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib260","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-114-8-621","article-title":"Quality-of-life-adjusted evaluation of adjuvant therpies for operable breast cancer. The international breast cancer study group","volume":"114","author":"Gelber","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib270","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/pds.887","article-title":"Benefit\u2013risk analysis: a proposal using quantitative methods","volume":"12","author":"Holden","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib280","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/pds.794","article-title":"Benefit\u2013risk analysis: examples using quantitative methods","volume":"12","author":"Holden","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib290","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2165\/00002018-200528110-00001","article-title":"Risk management strategies in the post-marketing period: safety experience with the US and European boasentan surveillance programmes","volume":"28","author":"Segal","year":"2005","journal-title":"Drug Saf"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib300","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1055\/s-2007-992931","article-title":"Oral contraceptives in polycystic ovary syndrome: risk\u2013benefit assessment","volume":"26","author":"Yildiz","year":"2008","journal-title":"Semin Reprod Med"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib310","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00002018-200831010-00002","article-title":"Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature","volume":"31","author":"Tranulis","year":"2008","journal-title":"Drug Saf"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib320","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/00002018-200427040-00002","article-title":"Benefit\u2013risk assessment of tegaserod in irritable bowel syndrome","volume":"27","author":"Lea","year":"2004","journal-title":"Drug Saf"},{"issue":"Suppl. 11","key":"10.1111\/j.1524-4733.2010.00725.x_bib330","first-page":"S8","article-title":"Risk assessment in oncology clinical practice: from risk factors to risk models","volume":"17","author":"Lyman","year":"2003","journal-title":"Oncology"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib340","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1517\/14740338.1.1.5","article-title":"Risk\u2013benefit of HMG-CoA reducatase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia","volume":"1","author":"Chuck","year":"2002","journal-title":"Expert Opin Drug Saf"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib350","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00002018-199717060-00006","article-title":"A risk\u2013benefit assessment of iron-chelation therapy","volume":"17","author":"Porter","year":"1997","journal-title":"Drug Saf"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib360","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2165\/00002018-199716010-00004","article-title":"A risk\u2013benefit assessment of losartan potassium in the treatment of hypertension","volume":"16","author":"Burrell","year":"1997","journal-title":"Drug Saf"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib370","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1377\/hlthaff.26.3.636","article-title":"What's more dangerous, your aspirin or your car? Thinking rationally about drug risks and benefits","volume":"26","author":"Cohen","year":"2007","journal-title":"Health Aff"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib380","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1345\/aph.1D401","article-title":"Interpretation of drug risk and benefit: individual and population perspectives","volume":"38","author":"Bjornson","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib390","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/J.1524-4733.2002.55150.x","article-title":"Odds ratio, relative risk, absolute risk reduction, and the number needed to treat\u2014which of these should we use?","volume":"5","author":"Schechtman","year":"2002","journal-title":"Value Health"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib400","series-title":"Modern Epidemiology","article-title":"Introduction to Categorical Statistics","author":"Rothman","year":"1998"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib410","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/bmj.316.7136.989","article-title":"When can odds ratios mislead?","volume":"316","author":"Davies","year":"1998","journal-title":"BMJ"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib420","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1001\/jama.287.21.2813","article-title":"Reporting number needed to treat and absolute risk reduction in randomized controlled trials","volume":"287","author":"Nuevo","year":"2002","journal-title":"JAMA"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib430","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/pds.1215","article-title":"Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics","volume":"16","author":"Califf","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib440","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women-principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Writing Group for the Women's Health Initiative Investigators","year":"2002","journal-title":"JAMA"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib450","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/pds.1435","article-title":"A quantitative approach to benefit\u2013risk assessment of medicines\u2014part 1: the development of a new model using multi-criteria decision analysis","volume":"16","author":"Mussen","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib460","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1002\/pds.1434","article-title":"A quantitative approach to benefit\u2013risk assessment of medicines\u2014part 2: the practical application of a new model","volume":"16","author":"Mussen","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(94)90026-4","article-title":"A new proposal for benefit-less-risk analysis in clinical trials","volume":"15","author":"Chuang-Stein","year":"1994","journal-title":"Control Clin Trials"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib480","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/cpt1979254381","article-title":"A scale for assessing the severity of diseases and adverse drug reactions. Application to drug benefit and risk","volume":"25","author":"Tallarida","year":"1979","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib490","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1200\/JCO.1986.4.12.1772","article-title":"A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer","volume":"4","author":"Gelber","year":"1986","journal-title":"J Clin Oncol"},{"issue":"Suppl. A","key":"10.1111\/j.1524-4733.2010.00725.x_bib500","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/0305-7372(93)90060-5","article-title":"Evaluation of effectivenss: Q-TwiST","volume":"19","author":"Gelber","year":"1993","journal-title":"Cancer Treat Rev"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib510","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/jnci\/88.15.1039","article-title":"A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer","volume":"88","author":"Gelber","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib520","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.bjc.6604501","article-title":"Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer","volume":"99","author":"Sherrill","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib530","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1200\/JCO.1989.7.1.36","article-title":"Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis","volume":"7","author":"Goldhirsch","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib540","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1583\/07-2194.1","article-title":"A prospective clinical, economic, and quality-of-life analysis comparing endovascular aneurysm repair (EVAR), open repair, and best medical treatment in high-risk patients with abdominal aortic aneurysms suitable for EVAR","volume":"14","author":"Hynes","year":"2007","journal-title":"J Endovasc Ther"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib550","first-page":"3687","article-title":"Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA)","volume":"95","author":"Mounier","year":"2000","journal-title":"Blood"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib560","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0889-8588(05)70025-3","article-title":"Adjuvant interferon treatment for melanoma","volume":"12","author":"Agarwala","year":"1998","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib570","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1081\/BIP-120028509","article-title":"A quality-adjusted survival model (Q-TWiST) for advanced stage cancer","volume":"14","author":"Cole","year":"2004","journal-title":"J Biopharm Stat"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib580","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJM198806303182605","article-title":"An assessment of clinically useful measures of the consequences of treatment","volume":"318","author":"Laupacis","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib590","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/bmj.310.6977.452","article-title":"The number needed to treat: a clinically useful measure of treatment effect","volume":"310","author":"Cook","year":"1995","journal-title":"BMJ"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib600","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/bmj.312.7028.426","article-title":"The number needed to treat: a clinically useful mammogram in its proper context","volume":"312","author":"Chatellier","year":"1996","journal-title":"BMJ"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib610","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/107327489800500502","article-title":"High-dose chemotherapy in the adjuvant treatment of breast cancer: benefit\/risk analysis","volume":"5","author":"Djulbegovic","year":"1998","journal-title":"Cancer Control"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib620","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/0272-4332.204050","article-title":"Use of quality-adjusted life year weights with dose-response models for public health decisions: a case study of the risks and benefits of fish consumption","volume":"20","author":"Ponce","year":"2000","journal-title":"Risk Anal"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib630","article-title":"Using the incremental net benefit framework for quantitative benefit\u2013risk analysis in regulatory decision-making\u2014a case study of alosetron in irritable bowel syndrome","author":"Lynd","year":"2009","journal-title":"Value Health"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib640","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1471-2288-6-48","article-title":"Joint distribution approaches to simultaneously quantifying benefit and risk","volume":"6","author":"Shaffer","year":"2006","journal-title":"BMC Med Res Methodol"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib650","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJM199609053351003","article-title":"A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma","volume":"335","author":"Geerts","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib660","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(00)04522-0","article-title":"Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk\u2013benefit contours","volume":"357","author":"Shakespeare","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib670","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1539-6924.2008.01135.x","article-title":"Are adult patients more tolerant of treatment risks than parents of juvenile patients?","volume":"29","author":"Johnson","year":"2009","journal-title":"Risk Anal"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib680","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1464-5491.2009.02696.x","article-title":"Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents","volume":"26","author":"Hauber","year":"2009","journal-title":"Diabet Med"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib690","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/apc.2008.0064","article-title":"Benefits, risk, and uncertainty: preferences of antiretroviral-na\u00efve African Americans for HIV treatments","volume":"23","author":"Hauber","year":"2009","journal-title":"AIDS Patient Care STDS"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib700","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s00415-009-0084-2","article-title":"Multiple sclerosis patients' benefit\u2013risk preferences: serious adverse event risks versus treatment efficacy","volume":"256","author":"Johnson","year":"2009","journal-title":"J Neurol"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib710","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1089\/jwh.2006.0218","article-title":"Women's willingness to accept perceived risks for vasomotor symptom relief","volume":"16","author":"Johnson","year":"2007","journal-title":"J Womens Health"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib720","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/(SICI)1099-1050(1998110)7:7<595::AID-HEC381>3.0.CO;2-E","article-title":"Magnetic resonance imaging for the investigation of knee injuries: an investigation of preferences","volume":"7","author":"Bryan","year":"1998","journal-title":"Health Econ"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib730","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/(SICI)1099-1050(199806)7:4<373::AID-HEC348>3.0.CO;2-J","article-title":"Methodological issues in the application of conjoint analysis in health care","volume":"7","author":"Ryan","year":"1998","journal-title":"Health Econ"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib740","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/1099-1050(200006)9:4<295::AID-HEC520>3.0.CO;2-D","article-title":"Willingness to pay for improved respiratory and cardiovascular health: a multiple-format stated-preference approach","volume":"9","author":"Johnson","year":"2000","journal-title":"Health Econ"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib750","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/bja\/aeh123","article-title":"Patient preferences for acute pain treatment","volume":"92","author":"Gan","year":"2004","journal-title":"Br J Anaesth"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib760","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1053\/j.gastro.2007.04.075","article-title":"Crohn's disease patients' risk\u2013benefit preferences: serious adverse event risks versus treatment efficacy","volume":"133","author":"Johnson","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib770","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/WAD.0b013e318181e4c7","article-title":"Older Americans' risk\u2013benefit preferences for modifying the course of Alzheimer disease","volume":"23","author":"Hauber","year":"2009","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib780","doi-asserted-by":"crossref","first-page":"C72","DOI":"10.1016\/S0149-2918(98)80010-6","article-title":"Balancing risks versus benefits in drug therapy decisions","volume":"20","author":"Lasagna","year":"1998","journal-title":"Clin Ther"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib790","series-title":"Medicines and Risk\/Benefit Decisions","article-title":"Risk\u2013benefit decisions in product license applications","author":"Bass","year":"1987"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib800","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1055\/s-2007-996430","article-title":"Basic aspects of risk\u2013benefit analysis","volume":"25","author":"Beckmann","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib810","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2165\/00002018-200225120-00003","article-title":"A benefit\u2013risk assessment of class III antiarrhythmic agents","volume":"25","author":"Brendorp","year":"2002","journal-title":"Drug Saf"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib820","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1161\/01.CIR.99.3.377","article-title":"Reporting risks and benefits of therapy by use of the concepts of unqualified success and unmitigated failure; applications to highly cited trials in cardiovascular medicine","volume":"99","author":"Mancini","year":"1999","journal-title":"Circulation"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib830","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/annonc\/mdf209","article-title":"Assessment of the risk\/benefit ratio of phase II cancer clinical trials by Institutional Review Board (IRB) members","volume":"13","author":"Luijn","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1524-4733.2010.00725.x_bib840","first-page":"200","article-title":"What are the chances? Evaluating risk and benefit information in consumer health materials","volume":"92","author":"Burkell","year":"2004","journal-title":"J Med Libr Assoc"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830151060109X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830151060109X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T08:11:47Z","timestamp":1559031107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109830151060109X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":84,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S109830151060109X"],"URL":"https:\/\/doi.org\/10.1111\/j.1524-4733.2010.00725.x","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}